CARTANA
CARTANA is a Swedish Biotechnology company that maps gene expression in brain tissue via In Situ Sequencing (ISS).
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
SEK425m | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 513 % | 331 % | (94 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (545 %) | 8 % | 2084 % | (143 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (571 %) | - | 1647 % | 955 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cartana, a pioneering company in the field of spatial genomics, provides cutting-edge solutions for advanced biological research and discovery. The company specializes in developing high-resolution spatial transcriptomics technology, which allows researchers to visualize gene expression in tissue samples with unprecedented detail. This technology is crucial for understanding complex biological systems and diseases at the molecular level. Cartana serves a diverse range of clients, including academic institutions, pharmaceutical companies, and biotechnology firms, operating primarily in the life sciences market. The business model revolves around the sale of its proprietary reagents and kits, as well as offering specialized services and support to its clients. Revenue is generated through direct sales, partnerships, and collaborations with leading research institutions and companies.
Keywords: spatial genomics, transcriptomics, biological research, gene expression, tissue samples, molecular level, life sciences, reagents, biotechnology, pharmaceutical.